Lupin Limited has informed the Exchange regarding a press release dated September 17, 2025, titled "Lupin Receives Approval from U.S. FDA for Lenalidomide Capsules".
Press Release Sep 17 2025
Filed with NSE ·
6ix hasn’t read this filing yet.
Earlier from Lupin
- Lupin Receives U.S. FDA Approval for Risperidone Long-Acting Injectable, with 180-Day CGT Exclusivity, the First Product from its Nanomi's Long-Acting Injectable Platform
- Press Release Sep 03 2025
- Press Release Aug 20 2025
- Press Release Aug 12 2025
- Press Release Aug 11 2025
Later from Lupin
- Press Release Sep 24 2025
- Lupin Strengthens its Global Specialty Ophthalmology Business with Acquisition of VISUfarma from GHO Capital
- Press Release Sep 30 2025
- Press Release Oct 01 2025
- Press Release Oct 03 2025
Follow Lupin into a list and get an email when it puts out news.
Follow Lupin